Form 8-K NGM BIOPHARMACEUTICALS For: Feb 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- Goldman Sachs tech conference highlights AI spending outlook
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
NGM Biopharmaceuticals (NGM) PT Raised to $30 at Cowen
February 24, 2020 12:11 PM ESTCowen analyst Ritu Baral raised the price target on NGM Biopharmaceuticals (NASDAQ: NGM) to $30.00 (from $25.00) while maintaining an Outperform rating.
The analyst commented, "NGM presented topline biopsy data from Cohort 4 in their Ph2a. The data demonstrated impressive improvements in both fibrosis (38% vs 18% pbo)... More
